These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 1372581)

  • 1. Vitronectin in liver disorders: biochemical and immunohistochemical studies.
    Inuzuka S; Ueno T; Torimura T; Tamaki S; Sakata R; Sata M; Yoshida H; Tanikawa K
    Hepatology; 1992 Apr; 15(4):629-36. PubMed ID: 1372581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Changes in plasma vitronectin, fibronectin, and serum laminin P1 levels and immunohistochemical study of vitronectin in the liver of patients with chronic liver diseases].
    Tomihira M
    Fukuoka Igaku Zasshi; 1991 Jan; 82(1):21-30. PubMed ID: 1708742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distribution of vitronectin in plasma and liver tissue: relationship to chronic liver disease.
    Kobayashi J; Yamada S; Kawasaki H
    Hepatology; 1994 Dec; 20(6):1412-7. PubMed ID: 7527001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemistry of the hepatic extracellular matrix in acute viral hepatitis.
    Inuzuka S; Ueno T; Torimura T; Sata M; Abe H; Tanikawa K
    Hepatology; 1990 Aug; 12(2):249-56. PubMed ID: 2202635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The significance of colocalization of plasminogen activator inhibitor-1 and vitronectin in hepatic fibrosis.
    Inuzuka S; Ueno T; Torimura T; Tamaki S; Sugawara H; Sakata R; Kusaba N; Sata M; Tanikawa K
    Scand J Gastroenterol; 1997 Oct; 32(10):1052-60. PubMed ID: 9361180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Collagen-binding activity of plasma vitronectin in chronic liver disease.
    Yamada S; Kobayashi J; Murawaki Y; Suou T; Kawasaki H
    Clin Chim Acta; 1996 Aug; 252(1):95-103. PubMed ID: 8814365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S protein/vitronectin in chronic liver diseases: correlations with serum cholinesterase, coagulation factor X and complement component C3.
    Kemkes-Matthes B; Preissner KT; Langenscheidt F; Matthes KJ; Müller-Berghaus G
    Eur J Haematol; 1987 Aug; 39(2):161-5. PubMed ID: 2444458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum clusterin and vitronectin in alcoholic cirrhosis.
    Høgåsen K; Homann C; Mollnes TE; Graudal N; Høgåsen AK; Hasselqvist P; Thomsen AC; Garred P
    Liver; 1996 Apr; 16(2):140-6. PubMed ID: 8740849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma collagen-binding vitronectin activated by heparin and dextran sulfate in chronic liver disease.
    Yamada S; Kobayashi J; Kawasaki H
    Res Commun Mol Pathol Pharmacol; 1997 Sep; 97(3):315-24. PubMed ID: 9387191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic expression of c-Myb in chronic human liver disease.
    Kitada T; Seki S; Nakatani K; Kawada N; Kuroki T; Monna T
    Hepatology; 1997 Dec; 26(6):1506-12. PubMed ID: 9397991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultrastructural localization of Cu, Zn-SOD in hepatocytes of patients with various liver diseases.
    Saito T; Shinzawa H; Togashi H; Wakabayashi H; Ukai K; Takahashi T; Ishikawa M; Dobashi M; Imai Y
    Histol Histopathol; 1989 Jan; 4(1):1-6. PubMed ID: 2485185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of alpha-smooth muscle actin in liver diseases.
    Yu E; Choe G; Gong G; Lee I
    J Korean Med Sci; 1993 Oct; 8(5):367-73. PubMed ID: 8305144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue inhibitor of metalloproteinase-1 in the liver of patients with chronic liver disease.
    Murawaki Y; Ikuta Y; Idobe Y; Kitamura Y; Kawasaki H
    J Hepatol; 1997 Jun; 26(6):1213-9. PubMed ID: 9210606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thermolabile beta-2 macroglycoprotein (Hakata antigen) in liver disease: biochemical and immunohistochemical study.
    Fukutomi T; Ando B; Sakamoto S; Sakai H; Nawata H
    Clin Chim Acta; 1996 Nov; 255(2):93-106. PubMed ID: 8937753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of the membrane attack complex of complement and its inhibitors during human liver allograft transplantation.
    Conti F; Grude P; Calmus Y; Scoazec JY
    J Hepatol; 1997 Nov; 27(5):881-9. PubMed ID: 9382976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum tissue inhibitor of metalloproteinases in patients with chronic liver disease and with hepatocellular carcinoma.
    Murawaki Y; Yamamoto H; Kawasaki H; Shima H
    Clin Chim Acta; 1993 Sep; 218(1):47-58. PubMed ID: 8299219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of serum tissue inhibitor of metalloproteinases-1 in various liver diseases.
    Ueno T; Tamaki S; Sugawara H; Inuzuka S; Torimura T; Sata M; Tanikawa K
    J Hepatol; 1996 Feb; 24(2):177-84. PubMed ID: 8907571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma YKL-40: a new potential marker of fibrosis in patients with alcoholic cirrhosis?
    Johansen JS; Møller S; Price PA; Bendtsen F; Junge J; Garbarsch C; Henriksen JH
    Scand J Gastroenterol; 1997 Jun; 32(6):582-90. PubMed ID: 9200292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of serum type-IV collagen levels in various liver diseases. Measurement with a one-step sandwich enzyme immunoassay using monoclonal antibodies with specificity for pepsin-solubilized type-IV collagen.
    Ueno T; Inuzuka S; Torimura T; Oohira H; Ko H; Obata K; Sata M; Yoshida H; Tanikawa K
    Scand J Gastroenterol; 1992 Jun; 27(6):513-20. PubMed ID: 1631498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The changes and significance of red cell nature-immune-adhesion function in liver diseases at different stages].
    Wang HB; Zhang JW; Guo JX; Liu ZH
    Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(6):455-8. PubMed ID: 12887755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.